Clinical Trial
doi: 10.3109/03009749009102117.
Effect of MaxEPA in patients with SLE. A double-blind, crossover study
Affiliations
- PMID: 2186476
- DOI: 10.3109/03009749009102117
Item in Clipboard
Clinical Trial
Effect of MaxEPA in patients with SLE. A double-blind, crossover study
Scand J Rheumatol.
1990.
Abstract
Seventeen patients with moderately active SLE participated in a double-blind, crossover study on the effect of MaxEPA, using olive oil as the control substance. During the first 3 months, 8/17 on Max EPA but only 2/17 on the control substance clinically and serologically improved (p = 0.05), but at 6 months there was no difference. The beneficial effect (if any) of MaxEPA on the disease was short-lived.
Similar articles
-
Effects of Maxepa on serum lipids in hypercholesterolaemic subjects.Atherosclerosis. 1989 Dec;80(2):119-24. doi: 10.1016/0021-9150(89)90019-1. Atherosclerosis. 1989. PMID: 2692571 Clinical Trial.
-
Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study.Br J Rheumatol. 1993 Nov;32(11):982-9. doi: 10.1093/rheumatology/32.11.982. Br J Rheumatol. 1993. PMID: 8220938 Clinical Trial.
-
Effect of eicosapentaenoic acid rich menhaden oil and MaxEPA on the autoimmune disease of Mrl/l mice.Int Arch Allergy Appl Immunol. 1989;88(4):454-61. doi: 10.1159/000234732. Int Arch Allergy Appl Immunol. 1989. PMID: 2542168
-
[Polyunsaturated omega-3 fatty acids and systemic lupus erythematosus: what do we know?].Rev Bras Reumatol. 2014 Nov-Dec;54(6):459-66. doi: 10.1016/j.rbr.2013.12.002. Epub 2014 Sep 28. Rev Bras Reumatol. 2014. PMID: 25445629 Review. Portuguese.
-
Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.Pharmacotherapy. 2007 May;27(5):715-28. doi: 10.1592/phco.27.5.715. Pharmacotherapy. 2007. PMID: 17461707 Review.
Cited by
-
Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.RMD Open. 2022 Jun;8(2):e002167. doi: 10.1136/rmdopen-2021-002167. RMD Open. 2022. PMID: 35654458 Free PMC article.
-
Fish oil supplementation in patients with and without systemic lupus erythematosus: targeting pro-inflammatory and pro-resolving lipid mediators.Clin Exp Rheumatol. 2022 Nov;40(11):2196-2197. doi: 10.55563/clinexprheumatol/xxr27t. Epub 2022 Jul 21. Clin Exp Rheumatol. 2022. PMID: 35894061 Free PMC article.
-
Omega 3 fatty acids for prevention and treatment of cardiovascular disease.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003177. doi: 10.1002/14651858.CD003177.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2018 Jul 18;7:CD003177. doi: 10.1002/14651858.CD003177.pub3. PMID: 15495044 Free PMC article. Updated.
-
Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse.PLoS One. 2014 Jun 19;9(6):e100255. doi: 10.1371/journal.pone.0100255. eCollection 2014. PLoS One. 2014. PMID: 24945254 Free PMC article.
-
Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results.J Immunol Res. 2018 Oct 21;2018:5264195. doi: 10.1155/2018/5264195. eCollection 2018. J Immunol Res. 2018. PMID: 30420970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
